News
HC Wainwright & Co. Reiterates Buy on SAB Biotherapeutics, Maintains $6 Price Target
16 Apr 24
News, Price Target, Reiteration, Analyst Ratings
Chardan Capital Maintains Buy on SAB Biotherapeutics, Maintains $25 Price Target
16 Apr 24
News, Price Target, Analyst Ratings
Chardan Capital Maintains Buy on SAB Biotherapeutics, Adjusts Price Target To $25 (reverse stock split 1:10)
2 Apr 24
News, Price Target, Analyst Ratings
HC Wainwright & Co. Maintains Buy on SAB Biotherapeutics, Lowers Price Target to $6
2 Apr 24
News, Price Target, Analyst Ratings
SAB Biotherapeutics Announces Clinical Partnership With Naval Medical Research Center To Advance Potential Influenza Treatment
25 Mar 24
Biotech, News, General
Press releases
SAB Biotherapeutics Provides SAB-142 Trial Update
16 Apr 24
Press Releases
SAB Biotherapeutics to Present at INNODIA Annual Meeting
8 Apr 24
News, Health Care, Press Releases
SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference
4 Apr 24
Press Releases
SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results
29 Mar 24
Press Releases
SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment
25 Mar 24
Health Care, Press Releases
SAB Biotherapeutics to Present at the BIO CEO & Investor Conference
23 Feb 24
News, Health Care, Press Releases
SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
8 Feb 24
News, Press Releases
SAB Biotherapeutics Announces Executive Leadership Change
2 Feb 24
News, Management, Press Releases